The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
p53 polymorphisms: cancer implications
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“i1 i2 i3 i4 i5 i6 i7 i8 i9 i10 (41, 10,739) (1, 115) (2, 92) (5, 775) (2, 81) (4, 567) (7, 342) (1, 92) (13, 2,817) (5, 919) Transactivation domains Prolinerich domain DNA-binding domain Tetramerization domain”
The International HapMap Project
†The International HapMap Consortium, Genotyping centres: Baylor College of Medicine and ParAllele BioScience, Gibbs, R. A., Belmont, J. W., Hardenbol, P., Willis, T. D., Yu, F., Chinese HapMap Consortium, Yang, H., Ch'ang, L.-Y., et al. (2003) · Nature · doi:10.1038/nature02168 · Cited by 6,057
A second generation human haplotype map of over 3.1 million SNPs
The International HapMap Consortium (2007) · Nature · doi:10.1038/nature06258 · Cited by 4,438
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
Genome-wide association study identifies novel breast cancer susceptibility loci
Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D. P., Thompson, D., Ballinger, D. G., Struewing, J. P., Morrison, J., Field, H., Luben, R., et al. (2007) · Nature · doi:10.1038/nature05887 · Cited by 2,319
Self-citationVousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Cited by
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Self-citationThe first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Genetic variation in microRNA networks: the implications for cancer research
Ryan, B. M., Robles, A. I., & Harris, C. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2867 · Cited by 1,257
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
Self-citationMultifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Strebhardt, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3184 · Cited by 653
The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury
Kriegel, A. J., Liu, Y., Fang, Y., Ding, X., & Liang, M. (2012) · Physiological Genomics · doi:10.1152/physiolgenomics.00141.2011 · Cited by 533
Carter, H., Chen, S., Isik, L., Tyekucheva, S., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., & Karchin, R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1133 · Cited by 458
Zhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Mdm2-mediated ubiquitylation: p53 and beyond
Marine, J.-C., & Lozano, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.68 · Cited by 354
TSGene: a web resource for tumor suppressor genes
Zhao, M., Sun, J., & Zhao, Z. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks937 · Cited by 330
Using Epidemiology and Genomics to Understand Osteosarcoma Etiology
Savage, S. A., & Mirabello, L. (2011) · Sarcoma · doi:10.1155/2011/548151 · Cited by 303
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility
Swedish Low-risk Colorectal Cancer Study Group, Stacey, S. N., Sulem, P., Jonasdottir, A., Masson, G., Gudmundsson, J., Gudbjartsson, D. F., Magnusson, O. T., Gudjonsson, S. A., Sigurgeirsson, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.926 · Cited by 295
Brownell, S. E., Hekmat-Scafe, D. S., Singla, V., Chandler Seawell, P., Conklin Imam, J. F., Eddy, S. L., Stearns, T., & Cyert, M. S. (2015) · CBE—Life Sciences Education · doi:10.1187/cbe.14-05-0092 · Cited by 287
“p53 is mutated in more than 50% of cancers (Hollstein et al., 1991; Soussi et al., 1994; Whibley et al., 2009).”
BackgroundKotler, E., Shani, O., Goldfeld, G., Lotan-Pompan, M., Tarcic, O., Gershoni, A., Hopf, T. A., Marks, D. S., Oren, M., & Segal, E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.012 · Cited by 285
Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides
McGirt, L. Y., Jia, P., Baerenwald, D. A., Duszynski, R. J., Dahlman, K. B., Zic, J. A., Zwerner, J. P., Hucks, D., Dave, U., Zhao, Z., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611194 · Cited by 232
TP53 gain-of-function mutation promotes inflammation in glioblastoma
Ham, S. W., Jeon, H.-Y., Jin, X., Kim, E.-J., Kim, J.-K., Shin, Y. J., Lee, Y., Kim, S. H., Lee, S. Y., Seo, S., et al. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0126-3 · Cited by 213
Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2050 · Cited by 115
Control of p53 and NF-κB signaling by WIP1 and MIF: Role in cellular senescence and organismal aging
Salminen, A., & Kaarniranta, K. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.012 · Cited by 111
Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1688951 · Cited by 94
“P53 mutations found in 50% of the tumors left the growth out of control, promoting malignant development of the tumor [39,40], and were likely to be a clinical indicator of tumor [41,42].”
BackgroundTowards an understanding of the role of p53 in adrenocortical carcinogenesis
Wasserman, J. D., Zambetti, G. P., & Malkin, D. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.010 · Cited by 84
Regulation of MCP-1 chemokine transcription by p53
Hacke, K., Rincon-Orozco, B., Buchwalter, G., Siehler, S. Y., Wasylyk, B., Wiesmüller, L., & Rösl, F. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-82 · Cited by 63
“TNF-α activates p53 via NFκB by binding to the corresponding promoter [30], which is, however, counteracted by the HPV-E6-mediated degradation of p53 through the proteasomal pathway [31] or by p53 mutations in virusindependent forms of human cancer [32].”
BackgroundLeu, J. I.-J., Murphy, M. E., & George, D. L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009943117 · Cited by 47
Gruber, T. A., Chang, M. S., Sposto, R., & Müschen, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1438 · Cited by 38
Metadata
- Authors
- Whibley, C., Pharoah, P. D. P., & Hollstein, M.
- Venue
- Nature Reviews Cancer
- Published
- 2009-02
- Volume
- 9
- Issue
- 2
- Pages
- 95-107
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2057854840
- Cited by
- 665
- References
- 171
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.